Clinical Trial Detail

NCT ID NCT03379493
Title Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Recruitment Terminated
Gender
Phase Phase I
Variant Requirements No
Sponsors Eureka Therapeutics Inc.
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Burkitt lymphoma

mantle cell lymphoma

non-Hodgkin lymphoma

CLL/SLL

Therapies
Age Groups: adult senior

No variant requirements are available.